Institutional members access full text with Ovid®

Share this article on:

Osteonecrosis of the jaw & osteoporosis therapy

Kessenich, Cathy R. DSN, ARNP

doi: 10.1097/01.NPR.0000383662.52780.b0

According to a task force convened by the American Society of Bone and Mineral Research, the risk of osteonecrosis of the jaw (ONJ) associated with oral bisphosphonate therapy for osteoporosis is low and estimated at 1 in 10,000 and less than 1 in 100,000 patient-treatment years. Comparatively, the risk of ONJ in patients with cancer treated with high doses of intravenous bisphosphonates is higher and estimated at 1-10 per 100 patients treated.

Cathy R. Kessenich is a professor at the University of Tampa, Fla., and a nurse practitioner in private practice.

© 2010 Lippincott Williams & Wilkins, Inc.